CHAMPION-AF: Can a Heart Device Replace Blood Thinners?

Dr. James Whitfield

Imagine... uh, just imagine telling a patient who's been taking an oral anticoagulant every single morning, year after year, that they could... well, just stop. Just throw the bottle away. No more worrying about, you know, shaving cuts, or what happens if they trip on the rug. But- but here is the catch: instead of that little pill, they let you thread a catheter into their heart to plug a tiny pocket in the left atrium. It sounds... well, to a lot of patients, it sounds a bit like science fiction. Or a massive gamble.

Dr. Elena Rodriguez

It does! It- it really does. But physiologically, it actually makes a ton of sense. We're talking about the left atrial appendage... which is, think of it like a little windsock or a side pocket hanging off the left atrium. In a normal, healthy sinus rhythm, that pocket is constantly flushing blood out. But in AFib, when the upper chambers are just... kind of quivering, that pocket becomes a stagnant pool. And stagnancy, as we know in biology, is where the trouble starts. Over ninety percent... ninety percent! of stroke-causing clots in non-valvular AFib form right there in that one tiny, anatomically useless pocket. So the logical question is: why thin the blood in the entire body when you can just... plug the pocket?

Dr. James Whitfield

Exactly. But for the longest time, the medical community said, "Whoa, hold on." We only did that... we only plugged that pocket with something like the WATCHMAN FLX device when a patient literally couldn't tolerate blood thinners. Like, if they had recurrent GI bleeds or severe fall risks. It was a backup plan. But... uh, but then CHAMPION-AF comes along and completely flips the script. This study, which was just published in the New England Journal of Medicine on March 28, 2026, and presented at the ACC.26 Scientific Session... it didn't look at patients who couldn't take drugs. It tested left atrial appendage closure as a direct, first-line alternative to oral anticoagulants in patients who were perfectly fine candidates for long-term pill therapy. It is the first prospective, multinational, randomized trial to test whether LAA closure is noninferior to NOACs in this population.

Dr. Elena Rodriguez

Wait, so these weren't high-risk bleeding patients? They- they were just... your average, everyday AFib patients who would normally walk out of your clinic with an apixaban or rivaroxaban prescription?

Dr. James Whitfield

Precisely. They enrolled three thousand patients across 141 global sites. The mean age was 71.7 years, and about 31.9% were women. But look at the clinical scores. Their mean CHA2DS2-VASc score was 3.5, which... you know, that's a very real, moderately high risk for stroke. But their mean HAS-BLED score... the marker for bleeding risk... was only 1.3. That is remarkably low. These patients had absolutely no pressing clinical reason to avoid Direct Oral Anticoagulants. They were the ideal candidates for a daily pill, and CHAMPION-AF put them head-to-head against the device.

Dr. Elena Rodriguez

Okay, so... three years out. What actually happened? Because, I mean, a three-year follow-up on three thousand patients is... that's a massive dataset. The primary efficacy endpoint... which was a composite of cardiovascular death, stroke, or systemic embolism... occurred in 5.7% of the device group and 4.8% of the DOAC group. Now, statistically, that met the pre-specified threshold for noninferiority. The 95% confidence interval for the difference was -0.8 to 2.6 percentage points, which is... yeah, it's well within that 4.8% noninferiority margin. So, efficacy-wise... the device held its own. But the real headline, James, the place where the device really... shined, was safety. Specifically, non-procedure-related bleeding.

Dr. James Whitfield

Right, because that's the whole point of stopping the drug, right?

Dr. Elena Rodriguez

Exactly! In the device group, non-procedural bleeding was 10.9% compared to... get this... 19.0% in the DOAC group. That is a hazard ratio of 0.55. It cut the long-term bleeding risk nearly in half over three years. For a patient who is active, who loves to garden or hike, or who is just terrified of... of having a major bleed, that is a massive, tangible clinical win.

Dr. James Whitfield

It is. It really is. But... uh, as an internist, I have to play the skeptic for a second and look at the fine print. Because while noninferiority was met for that composite endpoint, if you tease apart the individual components... the rate of ischemic stroke... just the ischemic strokes, not hemorrhagic... was numerically higher with the device. It was 3.2% in the WATCHMAN FLX group versus 2.0% in the DOAC group. That's a... a real signal. It shows that plugging the appendage, while elegant, doesn't quite match the systemic, head-to-toe clot-preventing power of a systemic drug. And... and there's another catch. If you look at total major bleeding... including the bleeding that happens right during the procedure itself, the hematomas, the access site issues... the rates at three years were virtually identical: 5.9% for the device and 6.4% for DOACs. So, you're essentially borrowing safety from the future... you take a big safety risk upfront during the implant to buy yourself a lower bleeding risk years down the line.

Dr. Elena Rodriguez

Hmm, that is a really crucial nuance. You're front-loading the risk. And... and let's be real about what the device actually requires post-procedure. I think some patients have this idea that they get the WATCHMAN, they wake up, and they're done with pills forever. But that's not how it works. You need a transition phase. The heart's lining... the endocardium... has to actually grow over that metal device, which takes about three months. During that time, they are still on a DOAC plus aspirin, or dual antiplatelet therapy. And many of these patients end up on lifetime baby aspirin anyway. So it's- it's not a complete "get out of jail free" card for meds.

Dr. James Whitfield

No, it isn't. And that's why this trial is so fascinating. It doesn't mean the WATCHMAN FLX left atrial appendage closure device is the new, undisputed king. But it does mean it may be considered as an alternative to NOACs for patients who are eligible for both. It turns a clinical rigid guideline into a real, shared decision-making conversation at the bedside. If a patient is terrified of daily compliance, or has a lifestyle where bleeding is a constant threat, the device is a highly viable, evidence-backed option. If they want the absolute tightest protection against an ischemic clot and don't mind the daily pill, DOACs remain the gold standard. It's about autonomy, really.

Dr. Elena Rodriguez

Well said. It's giving patients a real choice with solid data behind it. Alright, I think that's a wrap on this one. Good chatting, James.

Dr. James Whitfield

Sounds good, Elena. Talk soon.